HUP0102546A2 - Szorongásos állapot vagy depresszió következtében kialakult idegi és viselkedési változások megelőzésére és/vagy kezelésére alkalmas neuroprotektív készítmények - Google Patents

Szorongásos állapot vagy depresszió következtében kialakult idegi és viselkedési változások megelőzésére és/vagy kezelésére alkalmas neuroprotektív készítmények

Info

Publication number
HUP0102546A2
HUP0102546A2 HU0102546A HUP0102546A HUP0102546A2 HU P0102546 A2 HUP0102546 A2 HU P0102546A2 HU 0102546 A HU0102546 A HU 0102546A HU P0102546 A HUP0102546 A HU P0102546A HU P0102546 A2 HUP0102546 A2 HU P0102546A2
Authority
HU
Hungary
Prior art keywords
depression
nervous
prevention
treatment
anxiety states
Prior art date
Application number
HU0102546A
Other languages
English (en)
Inventor
Claudio Cavazza
Original Assignee
Sigma-Tau Healthscience S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sigma-Tau Healthscience S.P.A. filed Critical Sigma-Tau Healthscience S.P.A.
Publication of HUP0102546A2 publication Critical patent/HUP0102546A2/hu
Publication of HUP0102546A3 publication Critical patent/HUP0102546A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

A találmány szerinti készítmény, amely a) acetil-L-karnitint vagyannak farmakológiailag elfogadható sóját, és b) hipericint vagylegalább 0,3 tömeg% hipericint tartalmazó Hypericum-extraktumot(Hypericum perforatum L.) tartalmaz, táplálékkiegészítő vagy valódigyógyszer formában szorongásos állapotok vagy depresszió következtébenfellépő idegi vagy viselkedési változások megelőzésére és/vagygyógyászati kezelésére alkalmazható. Ó
HU0102546A 1998-06-25 1999-06-17 Neuroprotective composition for the prevention and/or treatment of nervous and behavioural alterations due to anxiety states or depression HUP0102546A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT98RM000425A IT1299195B1 (it) 1998-06-25 1998-06-25 Composizione ad attivita' neuroprotettiva per la prevenzione ed il trattamento delle alterazioni nervose e comportamentali legate a stati
PCT/IT1999/000175 WO1999066914A2 (en) 1998-06-25 1999-06-17 Neuroprotective composition for the prevention and/or treatment of nervous and behavioural alterations due to anxiety states or depression, comprising acetyl-l-carnitine and hypericin

Publications (2)

Publication Number Publication Date
HUP0102546A2 true HUP0102546A2 (hu) 2001-10-28
HUP0102546A3 HUP0102546A3 (en) 2003-08-28

Family

ID=11406010

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0102546A HUP0102546A3 (en) 1998-06-25 1999-06-17 Neuroprotective composition for the prevention and/or treatment of nervous and behavioural alterations due to anxiety states or depression

Country Status (26)

Country Link
US (1) US6346282B1 (hu)
EP (1) EP1089744B1 (hu)
JP (1) JP2002518438A (hu)
KR (1) KR20010053059A (hu)
CN (1) CN1307479A (hu)
AT (1) ATE228369T1 (hu)
AU (1) AU756542B2 (hu)
BR (1) BR9912179A (hu)
CA (1) CA2334858C (hu)
DE (1) DE69904173T2 (hu)
DK (1) DK1089744T3 (hu)
EE (1) EE200000729A (hu)
ES (1) ES2188178T3 (hu)
HU (1) HUP0102546A3 (hu)
IL (1) IL140159A0 (hu)
IS (1) IS5765A (hu)
IT (1) IT1299195B1 (hu)
MA (1) MA26651A1 (hu)
NO (1) NO20006430L (hu)
NZ (1) NZ508882A (hu)
PL (1) PL194177B1 (hu)
PT (1) PT1089744E (hu)
SK (1) SK19302000A3 (hu)
TN (1) TNSN99135A1 (hu)
TR (1) TR200003736T2 (hu)
WO (1) WO1999066914A2 (hu)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6348495B1 (en) * 1996-06-06 2002-02-19 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Method for treating celiac disease
DE10015617A1 (de) * 2000-03-29 2001-10-04 Peter Laetzsch Migränemittel
US7208180B2 (en) * 2000-05-08 2007-04-24 N.V. Nutricia Method and preparation for the preventing and/or treating vascular disorders and secondary disorders associated therewith
US7226916B1 (en) 2000-05-08 2007-06-05 N.V. Nutricia Preparation for the prevention and/or treatment of vascular disorders
IT1317035B1 (it) * 2000-05-30 2003-05-26 Sigma Tau Healthscience Spa Integratore ad attivita' antiossidante comprendente unaalcanoilcarnitina ed una associazione di polifenoli estratti dal
US7407778B2 (en) * 2002-02-07 2008-08-05 Pettegrew Jay W Compounds, compositions and methods for treating neuropsychiatric disorders
US7700074B2 (en) * 2002-02-07 2010-04-20 Pettegrew Jay W Method and system for diagnosis of neuropsychiatric disorders including chronic alcoholism
DE10213571A1 (de) * 2002-03-26 2003-10-23 Lichtwer Pharma Ag Pflanzenextrakte und deren Anwendung
US7674482B2 (en) * 2002-08-27 2010-03-09 Targeted Medical Pharma Inc. Method and compositions for potentiating pharmaceuticals with amino acid based medical foods
US20040067986A1 (en) * 2002-10-04 2004-04-08 Nathan Sassover Neuro-degenerative inhibitor, neuro-endocrine modulator, and neuro-cerebral metabolism enhancer
US20060257842A1 (en) * 2003-05-29 2006-11-16 Pettegrew Jay W Cryopreservation media and molecules
WO2004110963A2 (en) * 2003-05-29 2004-12-23 Pettegrew Jay W Glycerophosphocholine and its derivatives for medical imaging neuropsychiatric disorders
US20050232911A1 (en) * 2004-04-19 2005-10-20 Schreiber Brian D Prevention and treatment of metabolic abnormalities associated with excess intramyocellular lipid
US20070065486A1 (en) * 2004-05-21 2007-03-22 Migco Limited Migraine remedy
US20060115555A1 (en) * 2004-12-01 2006-06-01 Foulger Sidney W Nutritional supplements containing xanthone extracts
US20060115556A1 (en) * 2004-12-01 2006-06-01 Foulger Sidney W Nutritional supplement drink containing xanthone extracts
EP1854486A3 (de) * 2006-03-14 2010-06-02 Wilfried P. Bieger Verwendung von Neurotransmitter-Derivaten zur Herstellung von Mitteln zur Behandlung von neuroendokrinen gesundheitlichen Störungen
US8461389B2 (en) 2008-04-18 2013-06-11 University College Dublin, National University Of Ireland, Dublin Psycho-pharmaceuticals
US20110217252A1 (en) * 2008-11-11 2011-09-08 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Compound useful for treating cellulite
BRPI0900614A2 (pt) 2009-02-13 2011-06-28 Univ Fed Do Rio Grande Do Sul Ufrgs extrato vegetal neuroativo, composição farmacêutica compreendendo o mesmo e processo para sua produção
PT2582368T (pt) * 2010-06-16 2018-06-04 Alfasigma Spa Acetil-carnitina, para utilização num método para o aumento da neurogénese em tecido neuronal
US20150141380A1 (en) 2010-08-05 2015-05-21 Case Western Reserve University Inhibitors of erk for developmental disorders of neuronal connectivity
JP2014145857A (ja) 2013-01-28 2014-08-14 Sony Corp 表示装置およびその製造方法、並びに電子機器
WO2016126169A1 (ru) * 2015-02-04 2016-08-11 Общество С Ограниченной Ответственностью "Консорциум-Пик" Способ повышения эффективности терапии антидепрессантом в комплексной антидепрессивной терапии и фармацевтическая комбинация

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4346107A (en) * 1979-02-12 1982-08-24 Claudio Cavazza Pharmaceutical composition comprising acyl-carnitine for the treatment of impaired cerebral metabolism
DE4239959A1 (de) * 1992-11-27 1994-06-01 Schwabe Willmar Gmbh & Co Johanniskraut-Trockenextrakt, Verfahren zu seiner Herstellung und seine Verwendung
IT1276225B1 (it) * 1995-10-17 1997-10-27 Sigma Tau Ind Farmaceuti Composizioni farmaceutiche contenenti l-carnitina e alcanoil l- carnitine in associazione con resveratrolo o suoi derivati utili per
US5911992A (en) * 1997-06-12 1999-06-15 A. Glenn Braswell Method for controlling weight with hypericum perforatum and garcinia cambogia

Also Published As

Publication number Publication date
NO20006430L (no) 2001-02-21
CN1307479A (zh) 2001-08-08
US6346282B1 (en) 2002-02-12
IS5765A (is) 2000-12-08
PL345279A1 (en) 2001-12-03
ATE228369T1 (de) 2002-12-15
DE69904173D1 (de) 2003-01-09
IL140159A0 (en) 2002-02-10
SK19302000A3 (sk) 2001-09-11
BR9912179A (pt) 2001-04-10
TNSN99135A1 (fr) 2005-11-10
DE69904173T2 (de) 2003-08-28
AU756542B2 (en) 2003-01-16
EE200000729A (et) 2002-06-17
DK1089744T3 (da) 2003-03-24
PL194177B1 (pl) 2007-05-31
ITRM980425A1 (it) 1999-12-25
AU4391099A (en) 2000-01-10
KR20010053059A (ko) 2001-06-25
EP1089744A2 (en) 2001-04-11
JP2002518438A (ja) 2002-06-25
WO1999066914A3 (en) 2000-04-06
IT1299195B1 (it) 2000-02-29
TR200003736T2 (tr) 2001-06-21
WO1999066914A2 (en) 1999-12-29
CA2334858C (en) 2010-08-24
NZ508882A (en) 2002-06-28
PT1089744E (pt) 2003-04-30
HUP0102546A3 (en) 2003-08-28
ES2188178T3 (es) 2003-06-16
MA26651A1 (fr) 2004-12-20
ITRM980425A0 (it) 1998-06-25
CA2334858A1 (en) 1999-12-29
NO20006430D0 (no) 2000-12-15
EP1089744B1 (en) 2002-11-27

Similar Documents

Publication Publication Date Title
HUP0102546A2 (hu) Szorongásos állapot vagy depresszió következtében kialakult idegi és viselkedési változások megelőzésére és/vagy kezelésére alkalmas neuroprotektív készítmények
EP1292294A4 (en) USE OF TRIGLYCERIDES WITH MEDIUM CHAIN FOR THE TREATMENT AND PREVENTION OF ALZHEIMER'S DISEASE AND OTHER DISEASES CAUSED BY REDUCED NEURONAL METABOLISM
LT2004060A (en) A composition for treating neurocerebrovascular disorders
ATE374029T1 (de) Behandlung der alzheimer-krankheit durch erhöhung des cytidin-spiegels in vivo
AU2003269167A8 (en) Methods of purifying cannabinoids from plant material
TW200608979A (en) Pyrrolotriazine derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
KR930021110A (ko) 소나무 추출물의 기호성 개선 방법 및 이 방법에 의하여 제조되는 경구 섭취물
ATE540678T1 (de) Prodrugs aus gaba-analoga, zusammensetzungen und ihre verwendungen
DE69213010D1 (de) Verwendung eines Bakteriozin antibiotischen Agenten zur Herstellung eines Arzneimittels zur Behandlung von Magenverstimmungen, die durch Helicobacter pylori verursacht werden.
WO2001030335A3 (en) Pharmaceutical compositions useful in the prevention and treatment of beta-amyloid protein-induced disease
CO5190674A1 (es) Tratamiento de desordenes neuroticos desordenes neuroticos
WO1998032428A3 (en) Compositions comprising choline and use of choline to treat endotoxic shock
BG105275A (en) Tan-1057 derivatives
ATE253904T1 (de) Verwendung von pharmazeutische zusammensetzungen enthaltend thymol und/oder carvacrol in der behandlung von histomoniasis
ES2162520T3 (es) Medicamentos basados en hiperforina y/o extractos de hiperforina.
DE60029571D1 (de) Auf chondroitinsulfat und chitosan basierte zusammensetzungen zur verhütung oder behandlung rheumatischer erkrankungen
BRPI0418749A (pt) composição herbal
MX9300203A (es) Compuestos policiclicos disubstituidos y composicion farmaceutica que los contiene.
BR0211223A (pt) Derivados de 4-aminociclohexanol substituìdos
ID27755A (id) Komposisi parfum
DK1212072T3 (da) Farmaceutisk præparat omfattende eukalyptus- og orangeolie
ATE268599T1 (de) Verwendung von beta-naphtaquinon derivaten zur herstellung eines arzneimittels mit einem hemmenden effekt auf die glutamatfreisetzung durch das gehirn
BR0108823A (pt) Composição farmacêutica para o tratamento da doença cerebrovascular cognitiva
KR950026514A (ko) 프로폴리스 함유 피부용 세정제
DE60126504D1 (de) Verwendung von gegen candida wirksamen mitteln zur behandlung von störungen der oralen und intestinalen mucosa

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: SIGMA-TAU INDUSTRIE FARMACEUTICHE RIUNITE S.P., IT

Free format text: FORMER OWNER(S): SIGMA-TAU HEALTHSCIENCE S.P.A., IT

FD9A Lapse of provisional protection due to non-payment of fees